INCY shares surge 5.5% after-hours as Q4 earnings beat expected and Piper Sandler raises price target to $110.

因塞特医疗

Incyte Initiates Coverage on Buy, PT $135 by HC Wainwright & Co.

Incyte: Barclays Maintains Overweight, PT Raised to $116 from $115

Incyte's 15min chart shows Bollinger Bands Narrowing and KDJ Death Cross.

Incyte

Prelude

Prelude Therapeutics surges as FDA approves trial for cancer candidate PRT12396.

Catalyst<ul> <li>Recent Bullish Engulfing and Hanging Man signals indicate a potential reversal in momentum for INCY.</li> <li>Most analysts rate INCY Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flows indicate negative trends for Small, Large, and Extra-large orders.</li> <li>There are differences in analyst ratings for INCY, with one firm maintaining a Neutral stance.</li></ul>

Key Factors

Incyte's Q4 earnings are forecast to show a 52.3% year-over-year increase with an EPS of $1.96. Incyte shares surged 5.5% after-hours as Piper Sandler raised its price target to $110 and highlighted a potential Q4 earnings beat. Barclays raised Incyte's price target to $116 from $115, maintaining its Overweight rating. HC Wainwright & Co. initiated coverage on Incyte with a Buy rating and a price target of $135.

Recent Updates

INCY News